This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.
≥ 19 years of age and provided written informed consent
Histologically confirmed following large B-cell lymphomas according to the World Health Organization classification 2017
Diffuse large B-cell lymphoma, not otherwise specified Including Large cell transformation from follicular lymphoma (Transformed follicular lymphoma)
High-grade B-cell lymphoma, not otherwise specified
Patients with the following medical history
Adequately treated basal cell or squamous cell carcinoma without evidence of recurrence for at least 3 years prior to the study
In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to the study
A primary malignancy which has been completely resected and in complete remission for ≥ 5 years
Curocell Inc.
Lead sponsor